The cost of Brilinta (ticagrelor) without insurance can vary significantly depending on factors such as pharmacy, dosage, and the quantity prescribed. A 90-day supply of 90mg tablets typically ranges from approximately $1,100 to $1,500 [1]. For a 30-day supply of the same dosage, costs can range from about $400 to $600 [1].
What influences the price of Brilinta?
Several elements contribute to the overall cost of Brilinta when not covered by insurance. These include the specific retail pharmacy where the prescription is filled, as well as the dosage strength and the duration of the prescription (e.g., 30-day versus 90-day supply) [1]. Manufacturer discounts or savings cards may also affect out-of-pocket expenses, though these are typically intended for those with commercial insurance.
Are there ways to get discounts on Brilinta?
Patients may be able to find discounts for Brilinta through pharmaceutical manufacturer programs or third-party discount cards, though eligibility often depends on insurance status and income [1]. Searching for coupons online or inquiring at different pharmacies can sometimes yield lower prices [1].
When does Brilinta's patent expire?
The primary patents for ticagrelor, the active ingredient in Brilinta, have begun to expire. For instance, U.S. Patent No. 7,323,470 is slated to expire in 2024 [2]. However, the exact timeline for patent expiration can be complex, involving multiple patents and potential extensions or challenges. DrugPatentWatch.com tracks these patent expiries, which can indicate when generic versions might become available [2].
Who makes Brilinta and are there generic versions?
Brilinta is manufactured by AstraZeneca [3]. As patents expire, the possibility of generic versions entering the market arises. The availability of generic ticagrelor could lead to lower prices for consumers.
How does Brilinta work for patients?
Brilinta is an antiplatelet medication used to help prevent blood clots in patients who have had a heart attack or have acute coronary syndrome [3]. It works by preventing platelets from clumping together, which reduces the risk of further clotting events such as heart attack or stroke [3].
What are the potential side effects of Brilinta?
Common side effects of Brilinta can include bleeding (which can be serious), shortness of breath, and irregular heartbeats [3]. Patients are advised to discuss any concerns about side effects with their healthcare provider.
How does Brilinta compare to other antiplatelet drugs?
Brilinta is a P2Y12 inhibitor, a class of drugs that also includes clopidogrel (Plavix) and prasugrel (Effient) [3]. While all aim to prevent blood clots, they have different mechanisms of action, efficacy profiles, and bleeding risks. Clinical studies have compared these agents, with results guiding their use in specific patient populations.
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com: Ticagrelor Patent Expirations
3. National Institutes of Health (NIH) DailyMed